Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 1878-1884

  Pfister, Thomas D ^a   Reinhold, William C ^b   Agama, Keli ^b   Gupta, Shalu ^b   Khin, Sonny A ^a   Kinders, Robert J ^a   Parchment, Ralph E ^a   Tomaszewski, Joseph E ^b   Doroshow, James H ^b   Pommier, Yves ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; INDENOISOQUINOLINE DERIVATIVE; ISOQUINOLINE DERIVATIVE; NSC 724998; NSC 725776; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; LEUKEMIA CELL LINE; LUNG CANCER; MELANOMA CELL; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMILUMINESCENT MEASUREMENTS; DNA TOPOISOMERASES, TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INDENES; ISOQUINOLINES; MICROARRAY ANALYSIS; NATIONAL CANCER INSTITUTE (U.S.); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UNITED STATES;

EID: 67651176020     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0016     Document Type: Article

References (27)

1. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995;1262:1-14.
2. Ataka M, Ikeguchi M, Yamamoto M, et al. Topoisomerase I protein expression and prognosis of patients with colorectal cancer. Yonago Acta Medica 2007;50:81-7.
3. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS Trial. J Clin Oncol 2008;26:2690-8.
4. Boyer J, McLean EG, Aroori S, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004;10:2158-67.
5. Liao Z, Robey RW, Guirouilh-Barbat J, et al. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol Pharmacol 2008; 73:490-7.
6. Sorensen M, Sehested M, Jensen PB. Characterization of a human small-cell lung-cancer cell-line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 1995;72:399-404.
7. Burgess DJ, Doles J, Zander L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008;105:9053-8.
8. Durand-Faucher K, Rabinovitch-Chable H, Dzugan H, et al. A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples. Clin Chem Lab Med 2005;43:707-14.
9. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999;19:1720-30.
10. Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-32.
11. Coleman LW, Rohr LR, Bronstein IB, Holden JA. Human DNA topoisomerase I: an anticancer drug target present in human sarcomas. Hum Pathol 2002;33:599-607.
12. Lynch BJ, Komaromy-Hiller G, Bronstein IB, Holden JA. Expression of DNA topoisomerase I, DNA topoisomerase II-α, and p53 in metastatic malignant melanoma. Hum Pathol 1998;29:1240-5.
13. Liebes L, Potmesil M, Kim T, et al. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 1998;4:545-57.
14. Beidler DR, Cheng YC. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 1995;47:907-14.
15. Desai SD, Li T-K, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001;61: 5926-32.
16. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
17. Antony S, Agama KK, Miao ZH, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 2007;67: 10397-405.
18. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75:1262-71.
19. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31:e15.
20. Desai SD, Mao Y, Sun M, Li T-K, Wu J, Liu LF. Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance. Ann N Y Acad Sci 2000; 922:306-8.
21. Desai SD, Zhang H, Rodriguez-Bauman A, et al. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol 2003;23:2341-50.
22. Devy J, Wargnier R, Pluot M, Nabiev I, Sukhanova A. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines. Anticancer Res 2004;24:1745-51.
23. Zustovich F, Cartei G, Trestin A, et al. Analysis of topoisomerase (TOP) expression in peripheral blood mononuclear cell (PBMCs) from patients (PTS) undergoing chemotherapy (CHT) for solid tumors (ST). J Clin Oncol (Meet Abstr) 2004;22:2124.
24. Pommier Y, Barcelo JM, Rao VA, et al. Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 2006;81: 179-229.
25. Sordet O, Larochelle S, Nicolas E, et al. Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. J Mol Biol 2008;381:540-9.
26. Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 2000;35:385-402.
27. Hijiya N, Stewart CF, Zhou Y, et al. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer 2008;112:1983-91.